drugset / Trial / NCT02184234
Tolerability of Antistax® in Patients Suffering From Chronic Venous Insufficiency (CVI)
NaSingle-groupOpen-labelTreatment
Summary
Main objective: Safety and tolerability of Antistax® film coated tablets Secondary objective: Effect of Antistax® film coated tablets on subjective symptoms of chronic venous insufficiency
Timeline
- Start
- 2001-06
- Primary completion
- 2001-10
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Antistax | Unknown | 360 mg | Oral |